A Rigorous Multidisciplinary Theoretical Framework for Synergistic Bio- and Non-Biochemical Interventions to Reverse Cellular and Tissue Aging: Quantitative Stochastic Modeling, Clinical Applications, and Translational Precision Medicine

This comprehensive theoretical framework integrates biochemistry, bioengineering, applied mathematics, computational biology, and pharmacology to model synergistic bio- and non-biochemical interventions for cellular and tissue rejuvenation. We develop and rigorously analyze stochastic differential equation (SDE) models encompassing mitochondrial function, reactive oxygen species (ROS) dynamics, telomere attrition, cellular senescence, inflammaging, genomic instability, and---with expanded temporal sequencing---epigenetic drift, incorporating phased dynamics (early programmed vs. midlife-accelerated stochastic accrual at CpG sites, bifurcation ∼age 45 via Lyapunov stability μ_L ≈ 0.012 yr^{-1}), for precise multi-hallmark integration [tarkhov2025temporal]. Detailed derivations, drift-diffusion mechanics (Itô semimartingales with positivity-preserving reflections), numerical schemes (Euler--Maruyama Δt = 0.001 yr, weak order 1.0 via Richardson extrapolation O(Δt), strong O(√Δt) Milstein verification with <1% pathwise error), and empirical calibration (least-squares on residuals, maximum likelihood for distributions, hierarchical Bayesian with informative priors yielding 95% CIs via HPD intervals) ground in multi-omics cohorts (NHANES/UK Biobank/GTEx/TCGA). Innovations: (1) phased epi-SDE with hierarchy (σ_E' fast noise atop θ_t decay, bifurcation analysis); (2) hybrid SDE-ABMs (O(Δt) convergence, moment-matching up to order 4); (3) global sensitivity (EFAST Sobol n=4096, bootstrap CIs <0.05, full ANOVA decomposition R^2=0.99, epi-phased 20% network variance attribution); (4) PyMC v5 NUTS (4 chains, 2000 draws, thinning=10, \hat{R}<1.01, PPC Cramér--von Mises <5%); (5) TensorFlow 2.16 PINNs (composite loss MSE + PDE res. + entropy reg., Adam lr=1e-3, 5000 epochs, rel. error <2% on held-out trajectories). Liposomal NMN--fisetin PDEs (Godunov FV, efficiency >75%, RMSE <5% vs. PK trials). Simulations (n=2000, multiplicative noise, antithetic variates for variance reduction) baseline M(100) ≈ 2.7e-15 ± 1.1e-15 (CV=41%, 95% PI [1.2e-15,4.2e-15]); synergies ∼10^5× (p<10^{-12} Wilcoxon, KS D=0.95, Cohen's d=1.8, power=0.99). Hybrids: Moran's I=0.42 → 0.11 (spatial epi-clusters). Epi models capture 66--90% clock variance with phased fidelity [tarkhov2025temporal]. AI precision: digital twins for phased epi-forecasting, interpretable stratification in gene therapy (e.g., CRISPR-AI off-target <0.1% [nguyen2025crispr]). Trials: NCT04910061/NCT04313634. Ethics: Gini <0.2, federated learning. Replicable code (GitHub DOI), proofs (ℜ(λ)<0 pre-bifurc., μ_L>0 post), 2024--2025 lit. (AI-gene therapy, dissipation theory [khodaee2025dissipation]) ensure stringent cohesion and accuracy.